DeepCYP: an integrated deep learning web server for the holistic 'pathway-site product' prediction of CYP450 metabolism
Clinical Snapshot
PICO Framework
| P — Population | Small molecules (drugs and drug candidates) subject to cytochrome P450-mediated metabolism, evaluated in silico across nine major CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4) |
| I — Intervention | DeepCYP — a multi-task graph neural network (GNN) web server integrating multi-scale molecular descriptors and a mechanism-based reaction rule library for end-to-end CYP450 metabolic pathway, site-of-metabolism, and metabolite product prediction |
| C — Comparator | Established in silico CYP450 prediction tools: FAME3, SMARTCyp, and BioTransformer 3.0 |
| O — Outcomes | Top-1 and Top-2 site-of-metabolism ranking accuracy; metabolic pathway classification performance; metabolite product prediction fidelity; throughput (molecules per minute); interpretability features |
Bottom Line
DeepCYP is a computationally sophisticated, freely accessible web server that integrates deep learning with mechanistic reaction rules to predict CYP450 metabolic pathways, sites of metabolism, and metabolite products across nine clinically relevant isoforms in a unified pipeline. Its reported >10% improvement in Top-1 and Top-2 ranking accuracy over established tools (FAME3, SMARTCyp, BioTransformer 3.0) is promising, and its high-throughput capability and interpretability features offer genuine utility for drug discovery workflows. However, the absence of confidence intervals, statistical significance testing, and prospective experimental validation substantially limits confidence in the reported performance gains. The training dataset composition and independence from comparator tools' training data are not described, raising concerns about benchmarking fairness. Critically, this is an in silico tool with no patient-level validation — it should not be used to inform clinical prescribing or drug-drug interaction decisions. For Australian pharmaceutical researchers, DeepCYP represents a useful early-stage screening resource to prioritise compounds for experimental metabolic profiling, but outputs must be confirmed with in vitro microsomal assays or mass spectrometry-based metabolite identification before regulatory or clinical application. Senior clinicians should treat this as a hypothesis-generating tool, not a definitive metabolic profiling platform.
Key Findings
P Value: Not reported
Effect Size: DeepCYP improves Top-1 and Top-2 ranking metrics by over 10% compared to all three comparator tools
Primary Outcome: Top-1 and Top-2 site-of-metabolism ranking accuracy across nine CYP450 isoforms, benchmarked against FAME3, SMARTCyp, and BioTransformer 3.0
Nnt Or Sensitivity: Throughput: approximately 280 molecules per minute; specific sensitivity/specificity values for metabolic pathway classification not reported in abstract
Confidence Interval: Not reported
Clinical Application
High feasibility for integration into early-stage drug discovery pipelines. The freely accessible web server with batch processing capability (~280 molecules/minute) and no installation requirements lowers the barrier to adoption. Requires internet access and basic cheminformatics literacy. Not suitable as a standalone clinical decision-support tool without experimental validation of outputs. In the Australian context, DeepCYP is most relevant to pharmaceutical research institutions, university drug discovery centres, and biotechnology companies engaged in lead optimisation. The TGA requires comprehensive metabolic profiling data for new drug applications, and in silico tools such as DeepCYP can support early-stage ADMET (absorption, distribution, metabolism, excretion, toxicity) screening prior to costly in vitro and in vivo studies. The tool is not PBS-relevant in its current form. RACGP guidelines do not address in silico metabolic prediction tools. Clinicians should note that CYP2D6 and CYP2C19 polymorphisms are clinically significant in Australian populations (including Indigenous Australians and those of Asian descent), and the tool's lack of pharmacogenomic integration limits its direct clinical utility. For clinical drug-drug interaction assessment, TGA-approved prescribing information and established DDI databases remain the standard of care. Medicinal chemists, pharmacokineticists, and drug discovery scientists evaluating small molecule drug candidates for CYP450-mediated metabolic liability; not directly applicable to individual patient care
Abstract
CYP450 (cytochrome P450)-mediated drug metabolism is a critical determinant of pharmacokinetics and clinical safety, making comprehensive metabolic profiling essential for rational drug discovery. Here, we present DeepCYP (https://deepcyp.scbdd.com), a freely accessible deep-learning web server for end-to-end CYP450 metabolic profiling. Trained on an expanded dataset and a mechanism-based reaction rule library, DeepCYP uses a multi-task graph neural network (GNN) combined with multi-scale descriptors. Operating directly on 2D molecular graphs, this architecture bridges the entire "pathway-site-product" continuum across nine major CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) within a unified pipeline. Benchmarking demonstrates that DeepCYP outperforms established tools, including FAME3, SMARTCyp, and BioTransformer 3.0, improving Top-1 and Top-2 ranking metrics by over 10%. Furthermore, the server supports high-throughput batch processing, capable of evaluating ~280 molecules per minute. DeepCYP also enhances interpretability through an interactive visualization interface, featuring susceptibility radar charts and dynamic transformation tables. By translating abstract predictions into biological insights, DeepCYP provides a practical tool to accelerate lead optimization and mitigate toxicity risks.
References
- 1.Zhou, Y., Yang, S., Wang, X., He, Y., Tian, Y., Yi, J., Wang, Y., Deng, Y., Jiang, D., & Cao, D. (2026). DeepCYP: an integrated deep learning web server for the holistic 'pathway-site product' prediction of CYP450 metabolism. Nucleic Acids Research. https://doi.org/10.1016/S0022-3565(25)12326-4
Related Research
CPT: pharmacometrics & systems pharmacology
Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration
2 Aug 2026
Journal of pharmacokinetics and pharmacodynamics
Diffusion models for virtual populations and pharmacometric simulations
1 Aug 2026
Journal of chemical information and modeling
HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases
29 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service